相关实验视频

Updated: Sep 19, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

克服结质瘤中temozolomide耐药性:最近的进展和机制性见解

Hengzeng Li¹, Yahui Wu², Yue Chen¹

¹Department of Medical Genetics & Cell Biology, School of Basic Medical Sciences, Zhengzhou University, Kexue Avenue 100, Zhengzhou, 450001, Henan, China.

Acta neuropathologica communications

|June 4, 2025

概括

质瘤中Temozolomide耐药性是复杂的,涉及DNA修复,遗传突变和瘤微环境. 新的策略针对这些途径,以提高化疗的有效性和患者的存活率.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

泰莫佐洛米德 (Temozolomide,简称TMZ) 是用于质瘤的主要化疗.
内在和获得的耐药性限制TMZ的临床疗效.
了解抵抗机制对于改善质瘤治疗至关重要.

研究的目的:

审查促进质瘤中TMZ耐药性的分子途径.
总结最近的进展和新的治疗方法来克服TMZ抵抗.
确定新兴的策略,以改善质瘤患者的治疗结果.

主要方法:

关于TMZ抗性的分子机制的综合文献综述.
对针对抗性途径的当前和新兴治疗策略的分析.
讨论新的药物输送系统,向疗法和免疫疗法.

主要成果:

关键的抵抗机制包括增强的DNA修复 (MGMT,MMR,BER),遗传突变,非编码RNA,质瘤干细胞,自和瘤微环境.
进步包括纳米粒子传递,排放输送器抑制,并准DNA修复和自.
新兴疗法包括免疫疗法,代谢策略,CRISPR基因编辑和新的TMZ类似物.

结论:

克服TMZ耐药性需要采取多方面的方法,针对各种分子通路.
新的治疗策略在增强TMZ疗效和延长质瘤患者的存活时间方面表现有前途.
对新兴疗法的持续研究对于推进质瘤治疗至关重要.

关键词:

化学抗药性化学抗药性是一种抗药性.质瘤是一种质瘤.泰莫佐洛米德 (Temozolomide) 是一种可怕的药物.治疗策略治疗策略

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...